Boston Scientific (BSX) Cash from Investing Activities (2009 - 2026)

Boston Scientific has disclosed Cash from Investing Activities across 18 years of filings, most recently posting -$591.0 million for Q1 2026.

• Cash from Investing Activities for Q1 2026 came in at -$591.0 million, down 18.2% year-over-year; the trailing twelve-month figure through Mar 2026 was -$2.7 billion (up 53.73% YoY), and the FY2025 annual result was -$2.6 billion, up 53.58% from the prior year.
• Cash from Investing Activities came in at -$591.0 million for Q1 2026 at Boston Scientific, down from -$512.0 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of -$29.0 million in Q2 2022 to a low of -$3.7 billion in Q4 2024.
• The 5-year median for Cash from Investing Activities is -$502.0 million (2025), against an average of -$794.3 million.
• Across the five-year window, Cash from Investing Activities sank 2796.55% in 2023 and surged 86.18% in 2025, its largest moves.
• Boston Scientific's Cash from Investing Activities stood at -$183.0 million in 2022, then sank by 475.41% to -$1.1 billion in 2023, then plunged by 251.76% to -$3.7 billion in 2024, then soared by 86.18% to -$512.0 million in 2025, then decreased by 15.43% to -$591.0 million in 2026.
• The last three Cash from Investing Activities figures came in at -$591.0 million (Q1 2026), -$512.0 million (Q4 2025), and -$502.0 million (Q3 2025), per Business Quant data.